Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Edward Wilson Sells 27,000 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Troy Edward Wilson sold 27,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $3.33, for a total value of $89,910.00. Following the transaction, the director now owns 350 shares of the company’s stock, valued at $1,165.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Puma Biotechnology Stock Up 2.9 %

Shares of NASDAQ PBYI traded up $0.09 during mid-day trading on Monday, hitting $3.20. The company had a trading volume of 184,707 shares, compared to its average volume of 495,880. The company has a market capitalization of $154.37 million, a PE ratio of 9.70 and a beta of 1.04. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.46 and a quick ratio of 1.38. Puma Biotechnology, Inc. has a 1-year low of $2.13 and a 1-year high of $7.73. The business’s 50-day simple moving average is $4.47 and its 200 day simple moving average is $4.86.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.12. Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. The company had revenue of $43.80 million for the quarter, compared to analysts’ expectations of $41.53 million. On average, analysts predict that Puma Biotechnology, Inc. will post 0.22 earnings per share for the current year.

Institutional Trading of Puma Biotechnology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Crestline Management LP raised its stake in Puma Biotechnology by 6.5% in the fourth quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 2,135 shares in the last quarter. Jump Financial LLC increased its position in shares of Puma Biotechnology by 26.6% during the third quarter. Jump Financial LLC now owns 24,690 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 5,190 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Puma Biotechnology during the first quarter worth about $57,000. Ritholtz Wealth Management acquired a new stake in shares of Puma Biotechnology during the fourth quarter worth about $66,000. Finally, Assenagon Asset Management S.A. increased its position in shares of Puma Biotechnology by 23.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 85,039 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 15,897 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on PBYI shares. StockNews.com upgraded Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 12th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, June 3rd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.